📊 PMN Key Takeaways
Is ProMIS Neurosciences Inc. (PMN) a Good Investment?
ProMIS Neurosciences is a pre-revenue pharmaceutical company with negative profitability and substantial cash burn, destroying shareholder value at a rate of $12.4M annually in operating cash flow. While the balance sheet demonstrates strength with $63.8M in cash and zero debt, providing approximately 5 years of runway, the absence of revenue generation and negative operating margins indicate the company has not yet achieved fundamental viability. Fundamentals reveal a high-risk development stage company without demonstrated commercial success.
ProMIS Neurosciences Inc. Key Strengths (PMN)
- Strong balance sheet with $63.8M cash and only $6.7M liabilities
- Zero debt and exceptional liquidity position (9.92x current ratio)
- Substantial stockholders' equity of $60.7M providing operational flexibility
- Minimal capital expenditure ($2.0K) indicating asset-light model
PMN Stock Risks: ProMIS Neurosciences Inc. Investment Risks
- Pre-revenue status with no commercial products generating income
- Operating loss of $8.6M with negative net income and zero profitability margins
- Negative operating cash flow of $12.4M annually signifies active capital destruction
- Pharmaceutical sector execution risk with high development failure rates and uncertain clinical outcomes
- Negative ROE (-13.6%) and ROA (-12.2%) demonstrate shareholder value destruction
Key Metrics to Watch
- Operating cash burn rate trajectory and remaining cash runway
- Clinical trial progress, regulatory approvals, and path to revenue
- Timing and success of first commercial product launch
- Operating expense trends and achievement of key development milestones
- Stockholders' equity changes and dilution from future financing needs
ProMIS Neurosciences Inc. (PMN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.92x current ratio provides a solid financial cushion.
PMN Profit Margin, ROE & Profitability Analysis
PMN vs Healthcare Sector: How ProMIS Neurosciences Inc. Compares
How ProMIS Neurosciences Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is ProMIS Neurosciences Inc. Stock Overvalued? PMN Valuation Analysis 2026
Based on fundamental analysis, ProMIS Neurosciences Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
ProMIS Neurosciences Inc. Balance Sheet: PMN Debt, Cash & Liquidity
PMN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: ProMIS Neurosciences Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $2.63 reflects profitable operations.
PMN Revenue Growth, EPS Growth & YoY Performance
ProMIS Neurosciences Inc. Dividends, Buybacks & Capital Allocation
PMN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for ProMIS Neurosciences Inc. (CIK: 0001374339)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| May 22, 2026 | 4 | xslF345X06/tm2615475-9_4seq1.xml | View → |
| May 22, 2026 | 4 | xslF345X06/tm2615475-8_4seq1.xml | View → |
| May 22, 2026 | 4 | xslF345X06/tm2615475-7_4seq1.xml | View → |
| May 22, 2026 | 4 | xslF345X06/tm2615475-6_4seq1.xml | View → |
| May 22, 2026 | 4 | xslF345X06/tm2615475-5_4seq1.xml | View → |
❓ Frequently Asked Questions about PMN
What is the AI rating for PMN?
ProMIS Neurosciences Inc. (PMN) has an AI grade of C with 75% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PMN's key strengths?
Claude: Strong balance sheet with $63.8M cash and only $6.7M liabilities. Zero debt and exceptional liquidity position (9.92x current ratio).
What are the risks of investing in PMN?
Claude: Pre-revenue status with no commercial products generating income. Operating loss of $8.6M with negative net income and zero profitability margins.
What is PMN's revenue and growth?
ProMIS Neurosciences Inc. reported revenue of N/A.
Does PMN pay dividends?
ProMIS Neurosciences Inc. does not currently pay dividends.
Where can I find PMN SEC filings?
Official SEC filings for ProMIS Neurosciences Inc. (CIK: 0001374339) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PMN's EPS?
ProMIS Neurosciences Inc. has a diluted EPS of $-1.26.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PMN's fundamental grade?
Based on our AI fundamental analysis in June 2026, ProMIS Neurosciences Inc. has a C grade with 75% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PMN stock overvalued or undervalued?
Valuation metrics for PMN: ROE of -13.6% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PMN's AI grade for 2026?
Our dual AI analysis gives ProMIS Neurosciences Inc. a combined C grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PMN's free cash flow?
ProMIS Neurosciences Inc.'s operating cash flow is $-12.4M, with capital expenditures of $2.0K.
How does PMN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -13.6% (avg: 15%), current ratio 9.92 (avg: 2).